Home » Pharmacology » Enzymes » Kinases » Glycogen Synthase Kinase 3 » NSC 693868

NSC 693868

Cat. No. 1937

Price and Availability

For NSC 693868 pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 1H-Pyrazolo[3,4-b]quinoxalin-3-amine

Biological Activity

Inhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC₅₀ values are 0.6, 0.4 and 1 μM for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively.

Technical Data

M.Wt:

185.19

Formula:

C₉H₇N₅

Solubility:

Soluble to 100 mM in DMSO

Purity:

>99 %

Storage:

Store at +4°C

CAS No:

40254-90-8

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Select another batch:

Safety Data Sheet: View Safety Data Sheet

References

Monge et al (1995) 3-Amino-2-quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity. J.Heterocycl.Chem. 31 1135.

Ortega et al (2002) Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg.Med.Chem.Lett. 10 2177. PMID: 11983514.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Carbohydrate Metabolism Cell Cycle Cyclin-Dependent Protein Kinase

Glycogen Synthase Kinase 3 Kinases Wnt Signaling

Keywords: NSC 693868, supplier, GSK-3, inhibitors, cdks, GSK, Glycogen, Synthase, Kinases, 3, Cyclin-Dependent, Protein, Carbohydrate, Metabolism, NSC693868

Quick Order

Find multiple products by catalog number

Cancer Research Guide

Request your free copy

Highlights over 350 products for cancer research. Request a copy or view PDF today.

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Some of the most potent
kinase inhibitors all on one plate

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.